These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 37224887)

  • 1. ApoE4-mediated blood-brain barrier damage in Alzheimer's disease: Progress and prospects.
    Zhou X; Shi Q; Zhang X; Gu L; Li J; Quan S; Zhao X; Li Q
    Brain Res Bull; 2023 Jul; 199():110670. PubMed ID: 37224887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. iPSC-derived blood-brain barrier modeling reveals APOE isoform-dependent interactions with amyloid beta.
    Ding Y; Palecek SP; Shusta EV
    Fluids Barriers CNS; 2024 Oct; 21(1):79. PubMed ID: 39394110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accelerated pericyte degeneration and blood-brain barrier breakdown in apolipoprotein E4 carriers with Alzheimer's disease.
    Halliday MR; Rege SV; Ma Q; Zhao Z; Miller CA; Winkler EA; Zlokovic BV
    J Cereb Blood Flow Metab; 2016 Jan; 36(1):216-27. PubMed ID: 25757756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roles of ApoE4 on the Pathogenesis in Alzheimer's Disease and the Potential Therapeutic Approaches.
    Sun YY; Wang Z; Huang HC
    Cell Mol Neurobiol; 2023 Oct; 43(7):3115-3136. PubMed ID: 37227619
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Montagne A; Nikolakopoulou AM; Huuskonen MT; Sagare AP; Lawson EJ; Lazic D; Rege SV; Grond A; Zuniga E; Barnes SR; Prince J; Sagare M; Hsu CJ; LaDu MJ; Jacobs RE; Zlokovic BV
    Nat Aging; 2021 Jun; 1(6):506-520. PubMed ID: 35291561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline.
    Montagne A; Nation DA; Sagare AP; Barisano G; Sweeney MD; Chakhoyan A; Pachicano M; Joe E; Nelson AR; D'Orazio LM; Buennagel DP; Harrington MG; Benzinger TLS; Fagan AM; Ringman JM; Schneider LS; Morris JC; Reiman EM; Caselli RJ; Chui HC; Tcw J; Chen Y; Pa J; Conti PS; Law M; Toga AW; Zlokovic BV
    Nature; 2020 May; 581(7806):71-76. PubMed ID: 32376954
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-Expression of Glia Maturation Factor and Apolipoprotein E4 in Alzheimer's Disease Brain.
    Thangavel R; Bhagavan SM; Ramaswamy SB; Surpur S; Govindarajan R; Kempuraj D; Zaheer S; Raikwar S; Ahmed ME; Selvakumar GP; Iyer SS; Zaheer A
    J Alzheimers Dis; 2018; 61(2):553-560. PubMed ID: 29172001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Imipramine and olanzapine block apoE4-catalyzed polymerization of Aβ and show evidence of improving Alzheimer's disease cognition.
    Johnson NR; Wang AC; Coughlan C; Sillau S; Lucero E; Viltz L; Markham N; Allen C; Dhanasekaran AR; Chial HJ; Potter H
    Alzheimers Res Ther; 2022 Jun; 14(1):88. PubMed ID: 35768831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. APOE4 is a Risk Factor and Potential Therapeutic Target for Alzheimer's Disease.
    Ayyubova G
    CNS Neurol Disord Drug Targets; 2024; 23(3):342-352. PubMed ID: 36872358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How Alpha Linolenic Acid May Sustain Blood-Brain Barrier Integrity and Boost Brain Resilience against Alzheimer's Disease.
    Leikin-Frenkel A; Schnaider Beeri M; Cooper I
    Nutrients; 2022 Nov; 14(23):. PubMed ID: 36501121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic interaction between APOE and family history of Alzheimer's disease on cerebral amyloid deposition and glucose metabolism.
    Yi D; Lee Y; Byun MS; Lee JH; Ko K; Sohn BK; Choe YM; Choi HJ; Baek H; Sohn CH; Kim YK; Lee DY;
    Alzheimers Res Ther; 2018 Aug; 10(1):84. PubMed ID: 30134963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Important Interface Between Apolipoprotein E and Neuroinflammation in Alzheimer's Disease.
    Kloske CM; Wilcock DM
    Front Immunol; 2020; 11():754. PubMed ID: 32425941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opposing effects of viral mediated brain expression of apolipoprotein E2 (apoE2) and apoE4 on apoE lipidation and Aβ metabolism in apoE4-targeted replacement mice.
    Hu J; Liu CC; Chen XF; Zhang YW; Xu H; Bu G
    Mol Neurodegener; 2015 Mar; 10():6. PubMed ID: 25871773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apolipoprotein E and Alzheimer's Disease: Findings, Hypotheses, and Potential Mechanisms.
    Koutsodendris N; Nelson MR; Rao A; Huang Y
    Annu Rev Pathol; 2022 Jan; 17():73-99. PubMed ID: 34460318
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High ability of apolipoprotein E4 to stabilize amyloid-β peptide oligomers, the pathological entities responsible for Alzheimer's disease.
    Cerf E; Gustot A; Goormaghtigh E; Ruysschaert JM; Raussens V
    FASEB J; 2011 May; 25(5):1585-95. PubMed ID: 21266538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Roles of apolipoprotein E4 (ApoE4) in the pathogenesis of Alzheimer's disease: lessons from ApoE mouse models.
    Huang Y
    Biochem Soc Trans; 2011 Aug; 39(4):924-32. PubMed ID: 21787325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting ApoE4/ApoE receptor LRP1 in Alzheimer's disease.
    Martiskainen H; Haapasalo A; Kurkinen KM; Pihlajamäki J; Soininen H; Hiltunen M
    Expert Opin Ther Targets; 2013 Jul; 17(7):781-94. PubMed ID: 23573918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dysfunction of the blood-brain barrier in Alzheimer's disease: Evidence from human studies.
    Kurz C; Walker L; Rauchmann BS; Perneczky R
    Neuropathol Appl Neurobiol; 2022 Apr; 48(3):e12782. PubMed ID: 34823269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drugs targeting APOE4 that regulate beta-amyloid aggregation in the brain: Therapeutic potential for Alzheimer's disease.
    Poblano J; Castillo-Tobías I; Berlanga L; Tamayo-Ordoñez MC; Del Carmen Rodríguez-Salazar M; Silva-Belmares SY; Aguayo-Morales H; Cobos-Puc LE
    Basic Clin Pharmacol Toxicol; 2024 Sep; 135(3):237-249. PubMed ID: 39020526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of Alzheimer-like synaptic and cholinergic deficits in transgenic mice by human apolipoprotein E depends on isoform, aging, and overexpression of amyloid beta peptides but not on plaque formation.
    Buttini M; Yu GQ; Shockley K; Huang Y; Jones B; Masliah E; Mallory M; Yeo T; Longo FM; Mucke L
    J Neurosci; 2002 Dec; 22(24):10539-48. PubMed ID: 12486146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.